Immunotherapy has emerged as a transformative approach in the treatment of cancer and autoimmune diseases, leveraging the body's immune system to combat these conditions. However, the persistence of chronic inflammation poses a significant challenge, as it can disrupt immune balance and increase the risk of diseases such as cancer and metabolic syndrome. Tumors are often categorized as cold or hot based on their inflammatory immune cell and humoral factors, with cold tumors exhibiting low pro-inflammatory cytokines and higher immune checkpoint signaling, leading to T cell exhaustion and immunosuppression. This necessitates distinct immunotherapeutic strategies tailored to the tumor's immune microenvironment. Despite the advancements in immunotherapy, a critical gap remains in understanding the mechanisms behind immunotherapy resistance, which often results in poor or short-lived responses and disease recurrence. Addressing these challenges is crucial for achieving immune system reprogramming and sustained homeostasis in chronic inflammatory conditions.
This research topic aims to address the challenges associated with immune system reprogramming for sustained homeostasis, notably in the realm of chronic inflammation, encompassing conditions like cancer and autoimmune diseases. The primary objective is to unravel the complex mechanisms driving resistance to immunotherapy and to develop more effective strategies that enhance patient outcomes. Key questions include understanding the factors contributing to immunotherapy resistance, the role of the immune microenvironment, and the potential for novel therapeutic interventions. By exploring these areas, the research seeks to provide insights that can lead to improved immunotherapeutic approaches and better management of chronic inflammatory diseases.
To gather further insights into the complexities of immunotherapy resistance and chronic inflammation, we welcome articles addressing, but not limited to, the following themes:
- Exploring the hurdles encountered in the development and implementation of immunotherapeutic strategies for various chronic inflammatory diseases, including cancer and autoimmune conditions.
- Understanding the intricate interplay between the gut microbiota and the immune system, and how microbial composition influences the efficacy and response to immunotherapies.
- Genetic, epigenetic, and metabolic reprogramming influencing the response of cancer and chronic inflammatory patients to immunotherapies.
- Unraveling the complex mechanisms, intrinsic and extrinsic, that drive resistance to cancer immunotherapies.
- Novel adjuvants and combinatorial approaches for immunotherapies.
- Role of circadian rhythm in regulating the efficacy of immunotherapies, including vaccines.
Note that Topic Editor Sushmita Chakraborty is the Co-founder and Director of Proteinno Mab Tech. Please also note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by robust and relevant validation, are out of scope for this topic.
Immunotherapy has emerged as a transformative approach in the treatment of cancer and autoimmune diseases, leveraging the body's immune system to combat these conditions. However, the persistence of chronic inflammation poses a significant challenge, as it can disrupt immune balance and increase the risk of diseases such as cancer and metabolic syndrome. Tumors are often categorized as cold or hot based on their inflammatory immune cell and humoral factors, with cold tumors exhibiting low pro-inflammatory cytokines and higher immune checkpoint signaling, leading to T cell exhaustion and immunosuppression. This necessitates distinct immunotherapeutic strategies tailored to the tumor's immune microenvironment. Despite the advancements in immunotherapy, a critical gap remains in understanding the mechanisms behind immunotherapy resistance, which often results in poor or short-lived responses and disease recurrence. Addressing these challenges is crucial for achieving immune system reprogramming and sustained homeostasis in chronic inflammatory conditions.
This research topic aims to address the challenges associated with immune system reprogramming for sustained homeostasis, notably in the realm of chronic inflammation, encompassing conditions like cancer and autoimmune diseases. The primary objective is to unravel the complex mechanisms driving resistance to immunotherapy and to develop more effective strategies that enhance patient outcomes. Key questions include understanding the factors contributing to immunotherapy resistance, the role of the immune microenvironment, and the potential for novel therapeutic interventions. By exploring these areas, the research seeks to provide insights that can lead to improved immunotherapeutic approaches and better management of chronic inflammatory diseases.
To gather further insights into the complexities of immunotherapy resistance and chronic inflammation, we welcome articles addressing, but not limited to, the following themes:
- Exploring the hurdles encountered in the development and implementation of immunotherapeutic strategies for various chronic inflammatory diseases, including cancer and autoimmune conditions.
- Understanding the intricate interplay between the gut microbiota and the immune system, and how microbial composition influences the efficacy and response to immunotherapies.
- Genetic, epigenetic, and metabolic reprogramming influencing the response of cancer and chronic inflammatory patients to immunotherapies.
- Unraveling the complex mechanisms, intrinsic and extrinsic, that drive resistance to cancer immunotherapies.
- Novel adjuvants and combinatorial approaches for immunotherapies.
- Role of circadian rhythm in regulating the efficacy of immunotherapies, including vaccines.
Note that Topic Editor Sushmita Chakraborty is the Co-founder and Director of Proteinno Mab Tech. Please also note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by robust and relevant validation, are out of scope for this topic.